Seed Capital invests in Reapplix
The Danish company Reapplix has received an investment of DKK 7.6 million from SEED Capital.
Reapplix was founded in 2008 and has developed the product LeucoPatch for treatment of severe chronic foot ulcers. The product has revealed promising results on up to 10 year old wounds in a clinic study.
SEED Capital's investment will be used to conduct additional clinical efficacy studies of LeucoPatch on diabetic foot ulcers and prepare for commercialization of the product. Reapplix is the first investment from the newly raised SEED Capital Denmark II.
Read more
| Fund | SEED Capital Fund II |
| Portfolio Company | Reapplix |
| Date of Transaction | 2010-09-02 |
| Transaction | Acquisition, Finance round |
| Seller | |
| Buyer | |
| Size of Transaction | DKK 7.6m |
| Ind. Focus | Life Science |
| Geography | Denmark |
| Stage | Seed |